Abstract Number: 246 • 2012 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 (RAPID3) Is a Valid Index for Routine Care in Patients with Osteoarthritis
Background/Purpose: RAPID3 (routine assessment of patient index data) is an arithmetic composite index of three Core Data Set, patient self-report, measures: physical function (0-3 converted…Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting
Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis Patients with Pulmonary Involvement – the RIM Study
Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…Abstract Number: 208 • 2012 ACR/ARHP Annual Meeting
Outcome of Muscle Function and Disease Activity in Patients Recently Diagnosed with Polymyositis and Dermatomyositis – Preliminary Results of a 1-Year Follow-up Registry Study
Background/Purpose: Most patients with polymyositis (PM) and dermatomyositis (DM) develop sustained muscle impairment. The aim of this study was to evaluate the muscle endurance (Functional…Abstract Number: 209 • 2012 ACR/ARHP Annual Meeting
Clinical Study of Determination of Myositis-Associated Autoantibodies in Japanese Patients with Connective Tissue Diseases except Autoimmune Myositis
Background/Purpose: Anti-Jo-1 antibody is detected in the sera of patients with polymyositis/dermatomyositis (PM/DM). The antigen to which this antibody is directed is histidyl-tRNA synthase, an…Abstract Number: 210 • 2012 ACR/ARHP Annual Meeting
An Analysis of Metabolic Syndrome in Adult Dermatomyositis with a Focus On Cardiovascular Disease
Background/Purpose: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with increased cardiovascular risk. MetS has been systematically evaluated in all systemic autoimmune rheumatic…Abstract Number: 211 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review
Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)Methods:…Abstract Number: 212 • 2012 ACR/ARHP Annual Meeting
Distinctive Characteristics of Anti-Mi-2 and –p155/140 Autoantibody Production in Two Cohorts of Mexican Patients with Dermatomyositis
Background/Purpose: Various autoantibodies associated with a unique subset of polymyositis/dermatomyositis (PM/DM), including antibodies to Jo-1 and other synthetases, SRP, Mi-2, PM-Scl and others, have been…Abstract Number: 213 • 2012 ACR/ARHP Annual Meeting
Nsaids Suppress the Inflammatory Reaction Related to Muscle Soreness but May Delay Recovery
Background/Purpose: Eccentric muscle contraction causes an inflammatory reaction with pain peaking 24 to 48 hours after exercise – delayed onset of muscle soreness (DOMS). NSAIDs…Abstract Number: 214 • 2012 ACR/ARHP Annual Meeting
Inflammatory Muscle Disease Associated Pulmonary Hypertension – Clinical Features and Survival At a National Referral Centre
Background/Purpose: The association between connective tissue disease (CTD) and pulmonary hypertension (PH) is well known, especially in the scleroderma population. However, the association between inflammatory…Abstract Number: 215 • 2012 ACR/ARHP Annual Meeting
Abnormal Videofluoroscopy Swallow Study Finding in Inflammatory Myopathy Patient with Dysphagia As Predictor of Prognosis
Background/Purpose: Previous reports of dysphagia in patients with inflammatory myopathy (IM) have been focused on detection, intervention and rehabilitation. However, whether dysphagia with abnormal videofluoroscopy…Abstract Number: 216 • 2012 ACR/ARHP Annual Meeting
Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic connective tissue disorders, which are often associated with internal malignancy. Several studies have reported the association between…Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting
Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis
Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…Abstract Number: 218 • 2012 ACR/ARHP Annual Meeting
Proteomics Study of a Phase 1b Trial with an Anti-IFN-α Monoclonal Antibody Indicates Association of Soluble Interleukin 2 Receptor with Type I Interferon Activity in Patients with Dermatomyositis or Polymyositis
Background/Purpose: To evaluate downstream effects of an anti-IFN-α monoclonal antibody (mAb) in adult dermatomyositis (DM) and polymyositis (PM) patients using serum proteomics and gene expression…Abstract Number: 219 • 2012 ACR/ARHP Annual Meeting
Significant Functional Improvement Using Aggressive Immunomodulatory Therapy in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Background/Purpose: Pulmonary disease in patients with idiopathic inflammatory myopathies, polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM) is a major cause of morbidity. Approximately…Abstract Number: 220 • 2012 ACR/ARHP Annual Meeting
Efficacy of Rituximab for the Treatment of Refractory Inflammatory Myopathies Associated with Anti-Histidyl-tRNA Synthetase Antibodies (the FORCE Jo1 Study)
Background/Purpose: anti-histidyl-tRNA synthetase (anti-Jo1) antibodies are found in approximately 25–30% of patients with idiopathic inflammatory myopathies, frequently in the frame of an anti-synthetase syndrome characterized…